01—Abstract
Summary
Summary of the 10-K filed December 22, 2025. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported a 7% increase in net revenue to $6,948 milliona for the fiscal year ended October 31, 2025, compared to the previous year.
This growth was driven by strong performance across all segments and geographic regions, with the Life Sciences and Diagnostics Markets segment showing particular strength with an 11% increase, partly due to the acquisition of BIOVECTRA. The company's net income remained stable at $1,303 millionb, favorably impacted by tax benefits. Agilent continued its focus on operational efficiency, including a restructuring initiative aimed at optimizing management structure and achieving cost savings.
The company also actively managed its capital through share repurchases and dividend payments, demonstrating a commitment to shareholder returns. Despite the overall positive revenue trend, the company faced headwinds such as increased tariffs and shipping costs, which impacted gross margins. Agilent is actively implementing mitigation strategies to address these pressures.
The company also highlighted its ongoing investment in research and development to maintain its competitive edge and expand its product and solution portfolios. Looking forward, Agilent remains optimistic about the long-term health of its key end markets, despite some customer funding uncertainties, and anticipates continued growth through strategic investments and market expansion.
02—Key points
Key Highlights
- Agilent Technologies reported a 7% increase in net revenue to $6,948 million for the fiscal year ended October 31, 2025.
- The Life Sciences and Diagnostics Markets segment experienced an 11% revenue increase, boosted by the BIOVECTRA acquisition.
- Net income was $1,303 million, with tax benefits providing a favorable impact.
- The company is undergoing a restructuring initiative to optimize its management structure and achieve cost savings.
- Agilent returned capital to shareholders through share repurchases totaling $425 million and dividend payments of $282 million in fiscal year 2025.
- Gross margins were impacted by tariffs and shipping costs, leading Agilent to implement mitigation strategies.
- The company continues to invest in research and development to drive innovation and maintain its market position.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2025, Agilent Technologies, Inc. kept $0.19.
- Revenue$6.95B100.0%
- Cost of revenue−$3.31B47.6%
- Gross profit$3.64B52.4%
- Operating costs−$2.16B31.1%
- Operating income$1.48B21.3%
- Interest, other & tax−$176.0M2.5%
- Net income$1.30B18.8%
Where FY2025 revenue went
$6.95B- Cost of revenue: $3.31B, 48% of revenue
- SG&A: $1.71B, 25% of revenue
- Net income: $1.30B, 19% of revenue
- R&D: $455.0M, 6.5% of revenue
- Interest, other & tax: $176.0M, 2.5% of revenue
Kept 19% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2025filed December 22, 2025Financial Statements
FY2025 against FY2024
| Line item | FY2025FY2024 | Change |
|---|---|---|
| Revenue | $6.95B$6.51B | +6.7% |
| Cost of Revenue | $3.31B$2.98B | +11.1% |
| Gross Profit | $3.64B$3.54B | +3.1% |
| R&D Expenses | $455.00M$479.00M | −5.0% |
| SG&A Expenses | $1.71B$1.57B | +9.0% |
| Operating Expenses | $5.47B$5.02B | +8.9% |
| Operating Income | $1.48B$1.49B | −0.6% |
| Interest Expense | $112.00M$96.00M | +16.7% |
| Net Income | $1.30B$1.29B | +1.1% |
| EPS (Basic) | $4.59$4.44 | +3.4% |
| EPS (Diluted) | $4.57$4.43 | +3.2% |
| Shares Outstanding (Basic) | 284.00M290.00M | −2.1% |
| Shares Outstanding (Diluted) | 285.00M291.00M | −2.1% |
05—Questions
Frequently Asked Questions
What was Agilent's overall financial performance in fiscal year 2025?
Agilent Technologies reported a 7% increase in net revenue to $6,948 million for the fiscal year ended October 31, 2025, compared to the prior year. Net income remained strong at $1,303 million, supported by tax benefits.
Which segments drove revenue growth for Agilent?
The Life Sciences and Diagnostics Markets segment was the primary growth driver, with an 11% revenue increase. This growth was significantly influenced by the acquisition of BIOVECTRA, which contributed approximately 5 percentage points. The Agilent CrossLab segment also saw a 6% revenue increase, while the Applied Markets segment experienced a more modest 1% growth.
What challenges did Agilent face in fiscal year 2025, and how are they addressing them?
Agilent faced increased tariffs and shipping costs, which negatively impacted gross margins. To mitigate these pressures, the company is implementing strategies such as supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives. They also noted that continued funding and resource pressure on U.S. federal government agencies and their customers impacted business.
How did Agilent manage its capital and return value to shareholders?
In fiscal year 2025, Agilent repurchased approximately $425 million worth of its common stock under its repurchase programs and paid $282 million in cash dividends to shareholders, demonstrating a commitment to enhancing shareholder value.
06—Continue